Relation between clinical and anthropometric data and systemic inflammation in patients with COPD.
Recently, much attention is devoted to systemic inflammation in patients with chronic obstructive pulmonary disease (COPD). The aim of our study was to determine the relationship between clinical and anthropometric data with systemic inflammation in stable COPD patients. According to the study CRP levels were raised in 44% of patients(7.9 [7,1-10,9). Serum CRP was significantly higher in stable COPD patients than in control subjects (p=0.04). CRP correlated well with the pack/yearsindex(p = 0,032) and disease duration (p=0,01). It wasn’t established link between CRP levels and height, weight, stage, disease category. CRP level affected the frequency of exacerbations (r=0,50; p=0,01). Patients with high CRP level had significantly more exacerbations in the past year (p=0.01). Patients who received any type of therapyfor a long period of time had lower CRP levels, than patients who did not reseive any therapy.
Gashynova KY. [Systemic effects and comor¬bidity in outpatients with copd]. Ukr. Pulmonol. J. 2013;2:41–45. Ukrainian. 2. Gumeniuk MI. [Systemic inflammation markers in patients with chronic obstructive pulmonary disease]. Ukr. Pulmonol. J. 2014;3:33–36. Ukrainian. 3. [On approval and implementation of medical and technological documents on standardization of medical care in chronic obstructive pulmonary disease]: Order N 555 MoH of Ukraine. June 27; 2013. Ukrainian. 4. Feschenko YI. [Topical issues of chronic obstruc¬tive pulmonary disease]. Ukr. pulmonol. Zh. – 2010;1:6. Russian. 5. Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006;61(1):123-8. 6. Funda Aksu, Nermin Capan, Kurtulus Aksu1, Ruhsar Ofluoglu, Sema Canbakan, Bünyamin Yavuz, Kadir Okhan Akin. C-reactive protein levels are raised in stable Chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure. Journal of Thoracic Disease. 2013;5(4):414-21. 7. Rafea Shaaban, Sabine Kony, Fathi Driss, Bé¬nédicte Leynaert, David Soussan, Isabelle Pin, Fran¬çoise Neukirch, Mahmoud Zureik. Change in C-reactive protein levels and FEV1 decline: A longitudinal po¬pula¬tion-based study. Respiratory Medicine. 2006;100:2112-20. 8. Man SF, Xing L, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Zhang X, Vessey R, Walker TG, Celli BR, Sin DD. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Eur Respir J. 2008;32(6):1451-7. 9. Piehl-Aulin K1, Jones I, Lindvall B, Magnuson A, Abdel-Halim SM. Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pul¬monary disease. Respiration. 2009;78(2):191-6. 10. Lazovic B. Correlation of C-reactive protein and Serum Level of Fibrinogen with Severity of Disease in Chronic Obstructive Pulmonary Disease Patients. Med Arch. 2012;66:159-60. 11. Man SFP, Sin D.D. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:78–82. 12. Tang YJ1, Wang K, Yuan T, Qiu T, Xiao J, Yi Q, Feng YL. Salmeterol/fluticasone treatment reduces circulating C-reactive protein level in patients with stable chronic obstructive pulmonary disease. Chin Med J (Engl). 2010;123:1652-7. 13. Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. European Journal of Internal Medicine. 2008;19:104–8.
GOST Style Citations
This work is licensed under a Creative Commons Attribution 4.0 International License